(Q40549941)

English

Limited Access Trial Using Amifostine for Protection Against Cisplatin- and Three-Hour Paclitaxel–Induced Neurotoxicity: A Phase II Study of the Gynecologic Oncology Group

scientific article published on November 15, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Limited Access Trial Using Amifostine for Protection Against Cisplatin- and Three-Hour Paclitaxel–Induced Neurotoxicity: A Phase II Study of the Gynecologic Oncology Group (English)

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

toxic encephalopathy

1 reference

based on heuristic

inferred from title

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

author name string

James Donnelly

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Lois Almadrones

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Gynecologic Oncology Group

8

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

David H. Moore

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615449

1 April 2024

William P. McGuire

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615449

1 April 2024

David F. Cella

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615449

1 April 2024

Thomas J. Herzog

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615449

1 April 2024

Steven E. Waggoner

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615449

1 April 2024

language of work or name

0 references

publication date

1 November 2003

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

15 November 2003

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14615449

1 April 2024

full work available at URL

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2003.02.086

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

4207-4213

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study

2

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma

3

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

4

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

6

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Sequences of taxol and cisplatin: a phase I and pharmacologic study

7

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

8

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Cisplatin neuropathy: clinical course and neurophysiological findings

9

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Paclitaxel (taxol)

10

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer

11

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

13

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

14

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721.

17

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane).

19

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Phase I trials of WR-2721 and cis-platinum

23

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Phase I/II trials of WR-2721 and cis-platinum

24

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.

25

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer

26

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

27

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin.

28

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Recent advances in drug-induced neuropathies

29

1 reference

10.1200/JCO.2003.02.086

https://api.crossref.org/works/10.1200/JCO.2003.02.086

1 April 2024

Identifiers

10.1200/JCO.2003.02.086

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40549941&oldid=2116444870"